Terms: = Pancreatic cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
62 results:
1. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis.
Chen Y; Zhang F; Zhang B; Trojanowicz B; Hämmerle M; Kleeff J; Sunami Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1990. PubMed ID: 38389400
[TBL] [Abstract] [Full Text] [Related]
2. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast cancer.
Chi W; Xiu B; Xiong M; Wang X; Li P; Zhang Q; Hou J; Sang Y; Zhou X; Chen M; Zheng S; Zhang L; Xue J; Chi Y; Wu J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203393
[TBL] [Abstract] [Full Text] [Related]
3. Bioinformatics identification of a T-cell-related signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
Wang D; Ding D; Ying J; Qin Y
IET Syst Biol; 2023 Dec; 17(6):366-377. PubMed ID: 37935646
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study.
Xiang QM; Jiang N; Liu YF; Wang YB; Mu DA; Liu R; Sun LY; Zhang W; Guo Q; Li K
BMC Cancer; 2023 Oct; 23(1):1005. PubMed ID: 37858067
[TBL] [Abstract] [Full Text] [Related]
5. S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study.
Hao W; Zhang Y; Dou J; Cui P; Zhu J
BMC Cancer; 2023 Oct; 23(1):997. PubMed ID: 37853345
[TBL] [Abstract] [Full Text] [Related]
6. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract] [Full Text] [Related]
7. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE
De Monte L; Clemente F; Ruggiero E; Pini R; Ceraolo MG; Schiavo Lena M; Balestrieri C; Lazarevic D; Belfiori G; Crippa S; Balzano G; Falconi M; Doglioni C; Bonini C; Reni M; Protti MP
EBioMedicine; 2023 Nov; 97():104819. PubMed ID: 37776595
[TBL] [Abstract] [Full Text] [Related]
8. Molecular features, biological behaviors and clinical implications of m
Zhan M; Song H; Tian D; Wen Q; Shi X; Wang Y; Mao X; Wang J
Cancer Biol Ther; 2023 Dec; 24(1):2223382. PubMed ID: 37332118
[TBL] [Abstract] [Full Text] [Related]
9. Identification of a New m6A Regulator-Related Methylation Signature for Predicting the prognosis and Immune Microenvironment of Patients with pancreatic cancer.
Zou T; Shi D; Wang W; Chen G; Zhang X; Tian Y; Gong P
Mediators Inflamm; 2023; 2023():5565054. PubMed ID: 37181810
[TBL] [Abstract] [Full Text] [Related]
10. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in pancreatic cancer.
Kano MT; Kokuryo T; Baba T; Yamazaki K; Yamaguchi J; Sunagawa M; Ogura A; Watanabe N; Onoe S; Miyata K; Mizuno T; Uehara K; Igami T; Yokoyama Y; Ebata T; Nagino M
Anticancer Res; 2023 Mar; 43(3):1009-1016. PubMed ID: 36854520
[TBL] [Abstract] [Full Text] [Related]
11. Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.
Huang Q; Peng X; Li Q; Zhu J; Xue J; Jiang H
Front Immunol; 2023; 14():1111494. PubMed ID: 36817451
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract] [Full Text] [Related]
13. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.
Wang W; Zhang D; Chang D; Li Y; Ren L
Mol Cell Probes; 2023 Feb; 67():101897. PubMed ID: 36740149
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract] [Full Text] [Related]
15. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract] [Full Text] [Related]
16. Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration.
Barraud S; Tougeron D; Villeneuve L; Eveno C; Bayle A; Parc Y; Pocard M; André T; Cohen R
Dig Liver Dis; 2023 May; 55(5):673-678. PubMed ID: 36266207
[TBL] [Abstract] [Full Text] [Related]
17. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer.
Lu SY; Hua J; Liu J; Wei MY; Liang C; Meng QC; Zhang B; Yu XJ; Wang W; Xu J
BMC Med Genomics; 2022 Oct; 15(1):218. PubMed ID: 36261830
[TBL] [Abstract] [Full Text] [Related]
18. A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.
Zhu Z; Zhao Q; Song W; Weng J; Li S; Guo T; Zhu C; Xu Y
Front Immunol; 2022; 13():940774. PubMed ID: 36248908
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.
Giampietri C; Scatozza F; Crecca E; Vigiano Benedetti V; Natali PG; Facchiano A
J Transl Med; 2022 Oct; 20(1):467. PubMed ID: 36224560
[TBL] [Abstract] [Full Text] [Related]
20. Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.
Liu Z; Xu H; Weng S; Guo C; Dang Q; Zhang Y; Ren Y; Liu L; Wang L; Ge X; Xing Z; Zhang J; Luo P; Han X
Cancer Immunol Immunother; 2023 Mar; 72(3):599-615. PubMed ID: 35998003
[TBL] [Abstract] [Full Text] [Related]
[Next]
